Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Poly Medicure Ltd.
Swot
Poly Medicure Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Poly Medicure Ltd. has 16 Strengths, 10 Weaknesses, 1 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(16)
Weakness
(10)
Opportunity
(1)
Threats
(1)
Others
(1)
Companies with 10% increase in share price over three months, with rising net profit growth
Consistent Highest Return Stocks over Five Years
Stocks with Consistent Share Price Growth (subscription)
Relative Outperformance versus Industry over 1 Year
Companies with high TTM EPS Growth
Expensive Performers (DVM)
Annual Profit Growth higher than Sector Profit Growth
Dividend yield greater than sector dividend yield
Increasing Revenue every Quarter for the past 8 Quarters
Growth in Net Profit with increasing Profit Margin (QoQ)
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Companies with Low Debt
Increasing Revenue every Quarter for the past 4 Quarters
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
PEG greater than Industry PEG
High PE (PE > 40)
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Declining Net Cash Flow : Companies not able to generate net cash
Weak Momentum: Price below Short, Medium and Long Term Averages
Increasing Trend in Non-Core Income
RSI indicating price weakness
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter
Mutual Funds Increased Shareholding over the Past Two Months
MFs decreased their shareholding last quarter
Expensive Performers (DVM)